SalaryGuide
AboutPricingFor Employers

Marketing jobs

6 marketing jobs

Jazz Pharmaceuticals logo
10 days ago

Senior Manager, Global Capability Owner, Campaign Planning and Automation

Jazz Pharmaceuticals

USA (Remote)Full time$141K/yr – $211K/yr
Jazz Pharmaceuticals logo
4 weeks ago

Exec Director Product Marketing

Jazz Pharmaceuticals

Springfield, IL (Remote)Full time$280K/yr – $420K/yr
Jazz Pharmaceuticals logo
4 months ago

Associate Director, Market Access Marketing and Strategy

Jazz Pharmaceuticals

Philadelphia, PA (Remote)Full time$172K/yr – $258K/yr
Jazz Pharmaceuticals logo
4 months ago

Regional Marketing Manager- Solid Tumor Oncology (Southeast)

Jazz Pharmaceuticals

Alabama, USA (Remote)Full time$160K/yr – $240K/yr
Jazz Pharmaceuticals logo
4 months ago

Chief Communications Officer

Jazz Pharmaceuticals

Philadelphia, PA (Remote)Full time$340K/yr – $400K/yr
Jazz Pharmaceuticals logo
4 months ago

Regional Marketing Manager, West

Jazz Pharmaceuticals

Carson City, NV (On-site)Full time$172K/yr – $258K/yr

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

6 jobs
Jazz Pharmaceuticals logo

Senior Manager, Global Capability Owner, Campaign Planning and Automation

Jazz Pharmaceuticals

USA (Remote)

$141K/yr - $211K/yrIn-houseFull-timeSenior level8+ years exp.
10 days ago
Jazz Pharmaceuticals logo

Exec Director Product Marketing

Jazz Pharmaceuticals

Springfield, IL (Remote)

$280K/yr - $420K/yrIn-houseFull-timeSenior level12+ years exp.
4 weeks ago
Jazz Pharmaceuticals logo

Associate Director, Market Access Marketing and Strategy

Jazz Pharmaceuticals

Philadelphia, PA (Remote)

$172K/yr - $258K/yrIn-houseFull-timeSenior level7+ years exp.
4 months ago
Jazz Pharmaceuticals logo

Regional Marketing Manager- Solid Tumor Oncology (Southeast)

Jazz Pharmaceuticals

Alabama, USA (Remote)

$160K/yr - $240K/yrIn-houseFull-timeMid level
4 months ago
Jazz Pharmaceuticals logo

Chief Communications Officer

Jazz Pharmaceuticals

Philadelphia, PA (Remote)

$340K/yr - $400K/yrIn-houseFull-timeDirector/executive15+ years exp.
4 months ago
Jazz Pharmaceuticals logo

Regional Marketing Manager, West

Jazz Pharmaceuticals

Carson City, NV (On-site)

$172K/yr - $258K/yrIn-houseFull-timeSenior level5+ years exp.
4 months ago
Jazz Pharmaceuticals logo
Jazz Pharmaceuticals

Senior Manager, Global Capability Owner, Campaign Planning and Automation

USA (Remote)

$141K/yr – $211K/yrSenior Level8+ years expFull time

Posted 10 days ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Own the end-to-end Campaign Planning and Automation capability, shaping vision, roadmap, and governance across franchises; drive adoption, metrics, and cross-functional alignment, with emphasis on omnichannel orchestration and patient/HCP engagement.

Job Description

Responsibilities

  • Define the capability vision and outcomes aligned to global and franchise priorities in collaboration with key stakeholders.
  • Lead the ongoing evolution of the Campaign Planning and Automation roadmap, leveraging campaign analytics and user feedback to inform prioritization and trade-off decisions
  • Translate business needs into capability solutions with measurable success metrics that drive impact across franchises and the business.
  • Develop and maintain a roadmap that sequences campaign planning enhancements, automation/journey improvements, template and modular content enablement, segmentation and audience management improvements, Marketing CRM across SFMC and related tools to improve campaign execution efficiency and measurable performance.
  • Connect business stakeholders and the Omnichannel Orchestration and Campaign Planning global capability team, ensuring requirements are clearly defined and aligned to strategically important business outcomes and success metrics
  • Partner closely with business leads across franchises and functions to bring patient and HCP engagement strategies to life.
  • Partner closely with franchise Activation Leads to ensure capabilities effectively support activation needs, timelines, and in‑market execution across brands and end‑to‑end journeys.
  • Partner closely with the Tech Lead to align business priorities with technical feasibility and delivery sequencing, ensuring trade-offs support agreed business outcomes.
  • Partner closely with the Suite Lead to align capability priorities, scope and roadmap decisions with team-level business objectives, ensuring consistent focus on enterprise outcomes and value delivery.
  • Define clear capability requirements, user stories, and acceptance criteria to enable efficient execution and alignment with business partner activity needs.

Requirements

  • Bachelor’s degree in business, technology, marketing, science, or related field.
  • 8+ years of experience in pharmaceutical, healthcare, or other highly-regulated industries
  • Experience in digital product management, product ownership, or demonstrated experience managing the creation and delivery of a product roadmap within a cross-functional team.
  • Experience working with campaign planning platforms and executing campaigns in tools like SFMC / Marketing CRM.
  • Advanced degree may offset a portion of required years of experience, consistent with global hiring guidelines.
  • Experience working in a product operating model
  • Experience partnering with product teams supporting digital and operational capabilities.
  • Experience working in rare disease or specialty brands, with strong understanding of unique stakeholder dynamics.

Preferred

  • Advanced degree (MBA or relevant graduate degree) preferred.
  • Experience working in a product operating model
  • Experience partnering with product teams supporting digital and operational capabilities.
  • Experience working in rare disease or specialty brands, with strong understanding of unique stakeholder dynamics.

Benefits

  • medical, dental and vision insurance
  • 401k retirement savings plan
  • flexible paid vacation
Jazz Pharmaceuticals logo

Jazz Pharmaceuticals

3.3 Glassdoor

Jazz Pharmaceuticals plc (Nasdaq: JAZZ), is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are focused on developing life-changing medicines for people with serious diseases—often with limited or no options—so they can live their lives more fully. By transforming biopharmaceutical discoveries into novel medicines, we are working to give people around the world the opportunity to redefine what’s possible – to make the “small wins” big again. Founded in 2003 and headquartered in Dublin, Ireland, Jazz Pharmaceuticals has a significant corporate presence in Palo Alto, CA and Philadelphia, PA and in England in London, Oxford and Cambridge, with manufacturing facilities in Ireland, England and Italy. We maintain a highly collaborative culture where employees focus on how they can be successful and accomplish positive results by exemplifying the company’s core values: integrity, collaboration, passion, innovation and the pursuit of excellence. Together, we are experts, analysts, specialists, advocates, scientists and professionals all with diverse backgrounds and perspectives. Working together, we are proud to support patients, innovate and bring new medicines to patients with critical unmet needs. Please see our website at www.jazzpharma.com for more information. For information on recruitment, please visit https://careers.jazzpharma.com/. For guidelines on engaging with Jazz on social media, please visit https://bit.ly/2OaMOuq.

Founded in 2003
Dublin 4, County Dublin, IRL
3.6K employees (220 in marketing)
www.jazzpharma.com
56% recommend to a friend
66% CEO approval

Traffic Signals

Monthly Visitors
90K
Traffic Source Mix
Search
40.5%
Direct
40.2%
Referral
10.9%
Social
7.4%
Paid
0.8%

Headcount Trend

Current headcount: ~3.6K

Marketing Team

Marketing Team Size
197 (5% of company)
Marketing Roles Posted (Last 30 Days)
6

Funding

Total Funding
$2.8B
Last Raise
$850M
Post IPO Debt, 2 years ago

Funding History

  • Sep 2024
    Post IPO Debt • $850M
  • Apr 2021
    Post IPO Debt • $1.5B
  • Dec 2009
    Post IPO Debt • $120M

Recent News

Jazz Pharmaceuticals (JAZZ): Assessing Valuation Following Recent Net Income Growth and Share Price Recovery
Oct 11, 2025 • simplywall.st
Jazz Pharmaceuticals plc (JAZZ) Advances Rare Cancer Portfolio with First CNS Glioma Therapy Approval
Sep 23, 2025 • Yahoo Finance
Jazz Pharmaceuticals Showcases Phase 4 Data Demonstrating Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Effects and Real-World Evidence at World Sleep and Psych Congresses
Sep 22, 2025 • PR Newswire
Jazz Pharmaceuticals announces new evidence, Phase 4 data on Xywav
Sep 22, 2025 • thefly.com
Jazz Pharmaceuticals plc (JAZZ) Wins FDA Nod for Modeyso in Rare Pediatric Brain Tumors
Sep 16, 2025 • Yahoo Finance
Jazz Loses Bid To Block Avadel From Seeking Sleep Drug OK
Sep 16, 2025 • Law360
Amneal Receives U.S. FDA Approval of Sodium Oxybate Oral Solution
Sep 12, 2025 • BioSpace
Amneal Receives U.S. FDA Approval of Sodium Oxybate Oral Solution
Sep 11, 2025 • Amneal Pharmaceuticals LLC
Amneal Pharma up after US FDA approves sodium oxybate solution
Sep 11, 2025 • Reuters
Jazz Pharmaceuticals Secures Global Rights to SAN2355 in Licensing Deal with Saniona
Sep 10, 2025 • The Healthcare Technology Report.
Top biotech deals in August 2025
Sep 9, 2025 • Labiotech.eu
Jazz Pharmaceuticals' Modeyso recommended for glioma by NCCN Guidelines
Sep 9, 2025 • thefly.com
Modeyso™ (dordaviprone) Included in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for H3 K27M-mutant Diffuse Glioma
Sep 9, 2025 • MarketScreener
Modeyso™ (dordaviprone) Included in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for H3 K27M-mutant Diffuse Glioma
Sep 9, 2025 • PR Newswire
Roche receives CE IVDR approval for HER2 (4B5) companion diagnostic test to identify HER2-ultralow breast cancer and biliary tract cancer patients
Sep 5, 2025 • PR Newswire UK
Roche receives CE IVDR approval for HER2 (4B5) companion diagnostic test to identify HER2-ultralow breast cancer and biliary tract cancer patients
Sep 5, 2025 • BioSpace
Jazz Pharmaceuticals’ Pregnancy Study on Epidiolex: Key Insights for Investors
Aug 29, 2025 • TipRanks
Jazz Pharmaceuticals plc (JAZZ) Wins FDA Accelerated Approval for Modeyso™ Brain Cancer Therapy
Aug 29, 2025 • Yahoo Finance
Jazz Pharmaceuticals (JAZZ) Sings License with Saniona for SAN2355
Aug 28, 2025 • Yahoo Finance
Jazz Pharmaceuticals price target raised by $6 at RBC Capital, here's why
Aug 28, 2025 • thefly.com
Jazz Pharmaceuticals price target raised by $1 at Morgan Stanley, here's why
Aug 28, 2025 • thefly.com
FDA removes REMS program for the antipsychotic drug clozapine
Aug 28, 2025 • Pharma Letter
Jazz Pharmaceuticals price target raised by $5 at Truist, here's why
Aug 28, 2025 • thefly.com
US Narcolepsy Drugs Market Outlook and Company Analysis Report 2025-2033 Featuring Jazz Pharma, Ligand Pharma, Novartis, Takeda Pharma, Teva, Hikma, Harmony Biosciences, Roche - ResearchAndMarkets.com
Aug 25, 2025 • Business Wire
Jazz Pharmaceuticals to Participate in the 2025 Wells Fargo Healthcare Conference
Aug 21, 2025 • PR Newswire
Jazz Pharma inks deal with Saniona to develop SAN2355
Aug 21, 2025 • Pharma Letter
Jazz Pharmaceuticals to Participate in the 2025 Wells Fargo Healthcare Conference
Aug 21, 2025 • MarketScreener
FDA approves Jazz Pharmaceuticals’ Modeyso as first drug for ultra-rare brain cancer
Aug 20, 2025 • PMLiVE
Jazz Pharmaceuticals, Saniona Enter Exclusive Agreement
Aug 20, 2025 • Contract Pharma
Jazz Pharmaceuticals Enters Exclusive Licensing Agreement with Saniona to Develop and Commercialize SAN2355
Aug 20, 2025 • PR Newswire
Jazz pharmaceuticals acquires rights to Saniona’s epilepsy drug candidate
Aug 20, 2025 • Investing.com
Jazz Pharmaceuticals to Host Modeyso™ (dordaviprone) Investor Webcast on August 27, 2025
Aug 20, 2025 • PR Newswire
Jazz Pharmaceuticals and Saniona announce global license agreement
Aug 20, 2025 • thefly.com
Jazz Pharma Broadens Its Prospects in Epilepsy With Deal for Selective Saniona Drug
Aug 20, 2025 • MedCity News
Jazz pays Saniona $42.5M to add preclinical prospect to epilepsy ensemble
Aug 20, 2025 • FierceBiotech
Jazz Pharmaceuticals Receives Global Rights to Saniona's Epilepsy Drug in More Than $1 Billion Deal
Aug 20, 2025 • MarketScreener
Q2 Rundown: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Other Pharmaceuticals Stocks
Aug 17, 2025 • Yahoo Finance
Ziihera (zanidatamab), applicant: Jazz Pharmaceuticals Ireland Limited
Aug 16, 2025 • ec.europa.eu
Jazz Pharmaceuticals price target raised by $8 at BofA, here's why
Aug 14, 2025 • thefly.com
United States Narcolepsy Drugs Market to Reach US$ 2,233.56 Million by 2033 - 7.88% CAGR Driven by Novel Therapies and Better Diagnosis
Aug 14, 2025 • Research and Markets
Onco360 adds Modeyso™ (dordaviprone) to portfolio of Oncology and Rare Cancer therapies as a National Specialty Pharmacy Provider
Aug 13, 2025 • Onco360 Oncology Pharmacy
Psychedelic Drugs Market Size to Surpass USD 10.11 Billion by 2032, Fueled by Breakthrough Therapies and Expanding Mental Health Applications – SNS Insider
Aug 12, 2025 • SNS Insider pvt ltd
Gastric Cancer Market on Growth Trajectory: Novel Therapies Drive Momentum Through 2034 | DelveInsight
Aug 11, 2025 • DelveInsight Business Research LLP
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Aug 9, 2025 • simplywall.st
R&D developments of the past week: Life’s cosmic origins and quantum crystals meet AI’s democratization moment + GPT-5
Aug 8, 2025 • Research & Development World
FDA Approves Jazz Pharmaceuticals Modeyso to Treat Rare Brain Tumor
Aug 7, 2025 • Contract Pharma
New Treatment Option for H3 K27M-Mutant Glioma Treatment – Jazz Pharmaceuticals
Aug 7, 2025 • Oncodaily
Why Jazz Pharmaceuticals (JAZZ) Stock Is Trading Up Today
Aug 7, 2025 • Yahoo Finance
FDA gives accelerated approval to Jazz Pharma’s diffuse midline glioma therapy
Aug 7, 2025 • Pharmaceutical Technology
FDA approval of Modeyso for glioma
Aug 7, 2025 • Pharma Letter
Rare and Aggressive Brain Cancer Affecting Children Gets Its First FDA-Approved Drug
Aug 7, 2025 • MedCity News
Jazz gets FDA okay for Chimerix brain cancer drug
Aug 7, 2025 • pharmaphorum
Jazz Pharmaceuticals PLC (JAZZ) Q2 2025 Earnings Call Highlights: Strong Neuroscience ...
Aug 6, 2025 • Yahoo Finance
US FDA approves Jazz Pharma's drug for rare brain tumor
Aug 6, 2025 • Reuters
FDA Greenlights Jazz’s Dordaviprone, First New Treatment for Ultra-Rare Brain Tumor
Aug 6, 2025 • BioSpace
Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso™ (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma
Aug 6, 2025 • MarketScreener
Jazz's Modeyso becomes first FDA-approved drug for type of aggressive brain cancer
Aug 6, 2025 • FiercePharma
Chimerix buyout a win for Jazz with FDA nod for rare glioma drug
Aug 6, 2025 • BioWorld Financial Watch
Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso™ (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma
Aug 6, 2025 • PR Newswire
Jazz Pharmaceuticals price target lowered by $30 at Truist, here's why
Aug 6, 2025 • thefly.com
Jazz Pharmaceuticals Announces Second Quarter 2025 Financial Results and Updates 2025 Financial Guidance
Aug 5, 2025 • PR Newswire
Jazz Pharmaceuticals misses on Q2 earnings, shares fall
Aug 5, 2025 • Investing.com
Jazz Pharmaceuticals Reports Q2 2025 Results and CEO Transition
Aug 5, 2025 • TipRanks
Jazz Pharmaceuticals Announces Second Quarter 2025 Financial Results and Updates 2025 Financial Guidance
Aug 5, 2025 • PR Newswire UK
Jazz Pharmaceuticals reports Q2 adjusted EPS ($8.25), consensus ($6.25)
Aug 5, 2025 • thefly.com
Glioblastoma Funding Rises as Nonprofits Drive Interest and Pharma Returns to the Table
Aug 4, 2025 • BioSpace
Jazz Pharmaceuticals (JAZZ) To Report Earnings Tomorrow: Here Is What To Expect
Aug 3, 2025 • Yahoo Finance
Morgan Stanley Reduces PT on Jazz Pharmaceuticals plc (JAZZ) from $166 to $165; Maintains ‘Buy’ Rating
Jul 30, 2025 • Yahoo Finance
Earnings Preview: Jazz Pharmaceuticals (JAZZ) Q2 Earnings Expected to Decline
Jul 29, 2025 • Yahoo Finance
Compass Pathways Appoints Justin Gover to Board of Directors
Jul 29, 2025 • citybiz
Fund Update: Boston Trust Walden Corp added 229,885 shares of JAZZ PHARMACEUTICALS PLC ($JAZZ) to their portfolio
Jul 28, 2025 • Quiver Quantitative
Jazz Pharmaceuticals Q2 Earnings: Management to Host After-Hours Update on August 5
Jul 22, 2025 • Stock Titan
Jazz Pharmaceuticals price target lowered by $1 at Morgan Stanley, here's why
Jul 22, 2025 • thefly.com
Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 5, 2025
Jul 22, 2025 • PR Newswire UK
Lennox Gastaut Syndrome Market Research Report 2025-2035 | Regulatory Agencies Streamline Approval for Cutting-Edge Therapies, Pharmaceuticals Advance Novel AEDs
Jul 22, 2025 • Research and Markets
Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 5, 2025
Jul 22, 2025 • MarketScreener
Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 5, 2025
Jul 22, 2025 • PR Newswire
Why Alkermes Tumbled On Its Positive Narcolepsy Study
Jul 21, 2025 • Investor's Business Daily
Jazz Pharmaceuticals Stock Offers Buying Opportunity After Slump, Deutsche Bank Says
Jul 15, 2025 • MarketScreener
Jazz Pharmaceuticals initiated with bullish view at Deutsche Bank
Jul 15, 2025 • thefly.com
Jazz Pharmaceuticals (JAZZ) Highlights Growth at Goldman Sachs Healthcare Conference
Jul 14, 2025 • Yahoo Finance
Ireland: Renee Gala elected CEO at Jazz Pharma
Jul 14, 2025 • Investors in Healthcare
ASL Strategic Value Fund Issues Open Letter to Avadel Shareholders
Jul 14, 2025 • Business Wire
Cannabis Market Forecasts Report 2025-2030 | Key Dynamics, Porter's Analysis, Industry Value Chain Analysis, Policies and Regulations, & Strategic Recommendations
Jul 11, 2025 • GlobeNewswire News Room
Jazz Pharmaceuticals Names Renee Gala as President and Chief Executive Officer
Jul 10, 2025 • PR Newswire
New cadence at Jazz as Renee Gala replaces 16-year CEO Bruce Cozadd
Jul 10, 2025 • Fierce Pharma
Jazz Pharmaceuticals Names Renee Gala as President & CEO
Jul 10, 2025 • Contract Pharma
Why Jazz Pharmaceuticals Could Be Your Next Long-Term Buy
Jul 8, 2025 • Nasdaq
Is Jazz Pharmaceuticals Stock Undervalued At $110?
Jul 7, 2025 • Forbes
Jazz Pharmaceuticals Gets UBS Buy Rating After Strong ASCO 2025 Trial Results
Jul 2, 2025 • Yahoo Finance
EC approves Jazz Pharmaceuticals’ Ziihera for biliary tract cancer
Jul 2, 2025 • Pharmaceutical Technology
Jazz Pharmaceuticals Receives European Commission Marketing Authorization for Ziihera® (zanidatamab) for the Treatment of Advanced HER2-Positive Biliary Tract Cancer
Jul 1, 2025 • PR Newswire
The 5 Most Interesting Analyst Questions From Jazz Pharmaceuticals’s Q1 Earnings Call
Jun 27, 2025 • Yahoo Finance
Idiopathic Hypersomnia: Awakening a New Era in Sleep Disorder Therapeutics | Competitive Intelligence
Jun 23, 2025 • EIN Presswire
Tuberous Sclerosis Drug Market Forecast to 2034 – For Business Leaders, Analysts, and Strategic Teams
Jun 23, 2025 • EIN Presswire
EU reviews risk of abuse in some treatments for alcohol dependency
Jun 20, 2025 • MarketScreener
HER2-low Cancers Market Set to Register Immense Growth at a CAGR of 9.4% During the Study Period (2020-2034) | DelveInsight
Jun 19, 2025 • PR Newswire UK
HER2-low Cancers Market Set to Register Immense Growth at a CAGR of 9.4% During the Study Period (2020-2034) | DelveInsight
Jun 19, 2025 • PR Newswire
Jazz Pharmaceuticals plc Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 10:00 AM
Jun 11, 2025 • MarketScreener
Jazz Pharmaceuticals plc Presents Late-Breaking Phase 4 Data Showcasing Xywav®? (Calcium, Magnesium, Pot Pot Potent Treatment Outcomes in Narcolepsy At Sleep 2025
Jun 10, 2025 • MarketScreener